Sitemap

Posts

• Category: General Information
  • Does Stem Cell Line Qualify for Federal Funding?
  • The Number of Payday Loans Issued for Treatment Has Increased in the U.S.
• Category: Investors
  • Advanced Cell Technology Code Of Business Conduct And Ethics
• Category: Media Gallery
  • Dr. Robert Lanza Featured on ABC's Barbara Walters Special
• Category: News and Media
  • First red blood grown in the lab
  • Future of Stem Cell Tests May Hang on Defining Embryo Harm
  • Reprogrammed Cells Come Up Short, for Now
  • Scientists: Stem Cells Colonies Created Without Harming Embryos
• Category: Press Releases
  • ACT Announces Aberdeen Royal Infirmary in Scotland as Additional Site for Phase 1/2 Clinical Trial Using hESC-Derived RPE Cells for Macular Degeneration
  • ACT Announces Approval of Wills Eye Institute as Additional Site for Stem Cell Clinical Trial for Stargardt’s Disease
  • ACT Announces Approval to Treat Additional Stargardt’s Disease Patients with Higher RPE Dosage in Both U.S. and European Clinical Trials
  • ACT Announces Europe’s First Human Embryonic Stem Cell Transplant in Patient with Stargardt’s Disease
  • ACT Announces Filing of Definitive Proxy
  • ACT Announces First Patients Enrolled in Two Clinical Trials Using Embryonic Stem Cells to Treat Stargardt's Disease and Dry Age-Related Macular Degeneration
  • ACT Announces Massachusetts Eye and Ear as Additional Site for Clinical Trial for Dry Age-Related Macular Degeneration Using Human Embryonic Stem Cell-Derived RPE Cells
  • ACT Announces Positive Results from Two Clinical Trials Published in The Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells for the Treatment of Macular Degeneration
  • ACT Announces Second Patient with Stargardt's Disease Treated in EU Clinical Trial
  • ACT Announces that Additional Patient with Stargardt’s Disease Has Undergone Embryonic Stem Cell Transplantation at UCLA’s Jules Stein Eye Institute
  • ACT Announces Third Dry AMD Patient Treated in Clinical Trial
  • ACT Appoints Edward Myles as Chief Financial Officer
  • ACT Confirms Clinical Trial Participant Showed Improvement in Vision from 20/400 to 20/40 Following Treatment
  • ACT Confirms Clinical Trial Participant Showed Improvement in Vision from 20/400 to 20/40 Following Treatment
  • ACT Files Documentation With FDA for Clinical Trials Using ES Cells to Treat Eye Disease
  • ACT Granted EU Orphan Medicinal Product Designation for hESC-Derived RPE Cells for Treatment of Stargardt's Disease
  • ACT Issued Broad Patent for Human RPE Cells Derived From All Types of Pluripotent Stem Cells
  • ACT Publishes First Report of Embryonic Stem Cell (ESC)-Derived Cells Transplanted Into Patients
  • ACT Receives Approval from Data and Safety Monitoring Board (DSMB) to Treat Next Patients in Stem Cell Clinical Trials
  • ACT Reports the Publication of Research on the Scalable Generation of Universal Platelets from Human Induced Pluripotent Stem Cells (iPSC)
  • ACT Secures Approval to Proceed with Increased RPE Dosage for Patients in Clinical Trial for Dry AMD
  • ACT Treats 10th Patient in Embryonic Stem Cell Trials for Macular Degeneration
  • ACT Treats First Patient with Better Vision in Clinical Trial for Stargardt's Macular Dystrophy
  • ACT’s Clinical Partner Receives FDA Approval to Initiate Clinical Trial Using the Company’s hESC-derived Cells to Treat Severe Myopia
  • ACT’s Joint Venture SCRMI Reports in Prestigious Scientific Journal that Embryonic Stem Cells are a Potentially Unlimited Source of Functional Platelets for Transfusion
  • Advanced Cell and Colleagues Report Therapeutic Cells Derived From iPS Cells Display Early Aging
  • Advanced Cell Technology Achieves Clinical Milestone
  • Advanced Cell Technology Acquires Intellectual Property Assets of Infigen, Inc.
  • Advanced Cell Technology Acquires Intellectual Property Assets of Infigen, Inc.
  • Advanced Cell Technology and Catholic Healthcare West Sign Clinical Agreement
  • Advanced Cell Technology and Collaborators at The Casey Eye Institute Present Promising Data Supporting Safety and Efficacy of Stem Cell Therapy to Combat Retinal Disease
  • Advanced Cell Technology and The Burnham Institute Announce Collaboration to Isolate Stem Cell-Specific Differentiation Markers
  • Advanced Cell Technology Announces 2011 Financial Results
  • Advanced Cell Technology Announces 2012 Third Quarter Results
  • Advanced Cell Technology Announces Alternative Approach for Derivation
of Embryonic Stem Cell Lines
  • Advanced Cell Technology Announces Catheter Supply Agreement with Biologics Delivery Systems Group
  • Advanced Cell Technology Announces Change in Management